47 results about "Aneurysm dissecting" patented technology

An endoluminal medical device comprises a drug release system that releases a cathepsin inhibitor at a predetermined location within a lumen of a patient. The endoluminal devices and methods of treatment of disease can treat illnesses such as aneurysms and aortic dissections.

A radio frequency probe is positioned in a body lumen, and the body lumen is heated, using the radio frequency probe, to stabilize the body lumen for insertion of a stent graft or stent. Specifically, the heating shrinks a diameter the body lumen. In one example, blood is allowed to flow through the body lumen during the heating, and in another example, blood flow is blocked through the body lumen during the heating. Another method inserts a metallic mesh in an aneurysmal sac of an aortic aneurysm and expanding the metallic mesh to contact a wall of the aneurysmal sac. The metallic mesh is used to electro-coagulate blood from a Type II endoleak.

The invention discloses a method for forming an aortic stent graft. The method comprises the following steps: acquiring an image of aorta, and extracting a three-dimensional (3D) model of the aorta according to the image; extracting diameter characteristics of the aorta in the axial direction of the aorta of the 3D model; reconstructing an aortic vascular model according to the extracted diameter characteristics; 3D-printing a water-soluble vascular inner core according to the aortic vascular model; dip-coating a polymer film on a surface of the water-soluble vascular inner core; spirally weaving a metal mesh outside the treated water-soluble vascular inner core as a metal stent; bonding the polymer film and the metal stent, and then removing the water-soluble vascular inner core to obtain the aortic stent graft. The method provided by the invention can efficiently and accurately manufacture a vascular stent graft according to the actual size of a thoracic descending aorta of a patient based on a 3D printing technology, can effectively solve a detect that an existing equal-diameter vascular stent does not match a true vascular size of the patient, provides an effective medical means for treatment of acute vascular aneurysm, and has important clinical value.

This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and / or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

A stent graft assembly comprises a graft of flexible material supported by a stent frame that is configured to be deformable between an expanded state and a radially collapsed state. The graft of flexible material has the shape of a tube that is curved along a longitudinal axis of the tube when the graft is in an expanded, undeformed state. The stent graft assembly is deformable into a state in which the graft is deformed into the shape of a tube that is straight. The stent graft assembly may be designed for treatment of a thoracic aorta aneurysm.

The invention discloses application of N6022 in treatment of aortic dissection and aortic aneurysm, and relates to the field of cardiovascular diseases. In mouse models of aortic dissection and aorticaneurysm, dilation of aorta can be inhibited after intravenous injection of the N6022 into tail veins, thereby reducing incidence and mortality of aortic dissection and aortic aneurysm; and moreover,the N6022 is capable of reducing rupture of aortic aneurysm, inhibiting occurrence of hematoma in inner walls of lumen and excessive collagen deposition on vascular walls, maintaining integrity of elastic fibers in the vascular walls, and treating the aortic dissection and the aortic aneurysm. The application of the N6022 in the treatment of the aortic dissection and the aortic aneurysm opens upa new application field of the N6022, and provides a meaningful reference for the prevention and the treatment of the aortic dissection and the aortic aneurysm diseases as well as improvement of vascular lesions.

This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and / or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

The invention discloses application of FAM210B in the preparation of diagnostic tools for abdominal aortic aneurysm. Experiments prove that FAM210B has expression differences in normal control tissues and abdominal aortic aneurysm tissues; therefore, it is reckoned that FAM210B is a molecular marker for diagnosing abdominal aortic aneurysm. Experiments via in-vitro cultured cells prove that by accelerating the expression of FAM210B, it is possible to inhibit the apoptosis of human aortic smooth muscle cells; therefore, it is reckoned that FAM210B is a drug target for treating abdominal aortic aneurysm. As a new molecular marker for diagnosing and treating abdominal aortic aneurysm, the molecular marker has a promising clinical application prospect.

The invention relates to a set of serum markers for detection of aortic aneurysm / aortic dissection and application thereof. The set of serum markers can be individually used for or arbitrarily combined for distinguishing aortic aneurysm / aortic dissection patients and normal people. The serum markers are protein factors, which include: LCN2: lipocalin, SAA: serum amyloid protein A.

Tricyclic sulfonamide compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, renal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.

The invention belongs to image analysis, particularly relates to an aneurysm image analysis system and method based on double-flow boundary perception and equipment, and aims to solve the problem that an aneurysm image cannot be accurately analyzed according to a developed image in an existing image analysis technology. The method comprises the steps of obtaining a DSA image of a region containing aortic aneurysm as a to-be-detected image, and generating an aortic aneurysm boundary feature image and an aortic aneurysm image mask through a trained double-flow boundary sensing network based on the to-be-detected image, and obtaining morphological information of the aortic aneurysm image based on the aortic aneurysm image mask and the aortic aneurysm boundary features in combination with the DSA image. The extracted features are input into the double-flow boundary sensing network, and the boundary features and the mask image are extracted and fused at the same time, so that the accuracy of the aneurysm image is improved, the problem that the boundary of the aneurysm image is fuzzy in the prior art is solved, and morphological analysis of the aneurysm can be carried out more accurately.

The invention relates to a bare stent capable of being compressed in an axial direction. The bare stent is used for an aorta and is formed by overlapping and interweaving at least two first wires and second wires with different diameters, in a natural release state, the bare stent has a metal coverage rate of at least 30%, and the diameter of the first wires is 20-150 micrometers, and the diameter of the second wires is 150-600 micrometers. When the bare stent is used for treating aortic aneurysm and / or aortic dissection lesion, low liquid permeability and strong radial supporting force are provided for a needed part in the aorta through the axial compressibility of the stent.

The invention relates to a stent, a stent set and a stent delivery system. The stent is used in the aorta and is characterized in that the stent is formed by weaving at least two kinds of first silk and second silk with different diameters, the stent is constructed to be at least partially compressible and extensible in the axial direction of the stent in a natural release state, the first silk has the diameter of 20-150 microns, and the second silk has the diameter of 150-800 microns. When the stent is used for treating aortic aneurysm and / or aortic dissection lesions, low liquid permeability and strong radial supporting force are provided for the required part in the aorta through the axial compressibility and extensibility of the stent, and the stent is easily assembled into the delivery system with the proper diameter through the axial extensibility of the stent. The invention further provides the stent set comprising the stent and the stent delivery system.

The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of said disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.

The invention provides application of R-ketorolac in prevention and treatment of aortic dissection and aortic aneurysm. The R-ketorolac is orally taken to inhibit pathological expansion of aorta and reduce the occurrence rate and death rate of the aortic dissection and aortic aneurysm; and the R-ketorolac can inhibit the occurrence of vascular wall inflammatory reaction, reduce rupture of aortic aneurysm bodies, inhibit the occurrence of hematoma in the inner wall of a lumen, maintain the integrity of vascular wall elastic fibers and treat the aortic dissection and aortic aneurysm. The invention develops a new application field of the R-ketorolac, and provides a significant reference for preventing and treating aortic dissection and aortic aneurysm diseases and improving vascular lesion conditions.

The invention relates to the field of biomedicine, in particular to an effect of an exosome in thoracic aortic dissection / aneurysm. The survival rate of a normal mouse group within 30 days is 100%, the survival rate of an aortic dissection / aneurysm group established by using a BAPN drug to induce mice begins to be reduced at the beginning of the third week, the total survival rate is maintained at 50% at the fourth week of an experimental period, and on the basis, the exosome group is injected, so that the survival rate of the mice is slightly reduced after the third week, and the survival rate of the mice is maintained at 50% at the beginning of the third week. When the experiment period is 4 weeks, the survival rate is maintained at 70%. According to the data, the occurrence of thoracic aortic dissection / aneurysm can be obviously delayed after the exosome is injected.

The invention belongs to the technical field of aortic aneurysm auxiliary diagnosis, and particularly relates to a deep learning-based computed tomography aortic aneurysm auxiliary diagnosis method, which comprises the following steps of: 1, data acquisition: firstly, retrospectively collecting a plurality of common CT scans with aorta from a hospital area of a hospital; 2, data processing: dividing the data into three data sets: a training set, an internal test set and an external test set; and 3, establishing a model, constructing an auxiliary diagnosis tool by using an Attention-Unet convolutional neural network, evaluating the risk, detection sensitivity, specificity and accuracy of the aortic aneurysm in a test set by using the auxiliary diagnosis tool. The method is reasonable in design and has good diagnosis capability on aortic aneurysm; when the method is used in combination with radiologists, the film reading and decision-making capabilities of the radiologists can be remarkably enhanced, and the overall strength of imaging departments is improved. Therefore, the performance of the advanced technology proves that the non-invasive, cheap and convenient method has the potential of clinical tests.

A stent graft includes a tubular aortic component that defines a lumen and a fenestration with a pocket at the fenestration. At least one proximal tunnel graft extends proximally within the lumen from the proximal opening of the pocket and is secured at a proximal end to the tubular component, and at least one distal tunnel graft extends distally within the lumen from the distal opening of the pocket and is secured at a distal end to the tubular aortic component. The stent graft can further include at least one branch stent graft, each of which extends through the fenestration and within at least one of the proximal tunnel graft or the distal tunnel graft. The stent graft can be implanted in a patient to thereby treat an aneurysm, such as a suprarenal or thoracoabdominal aortic aneurysm.

The invention relates to a bare stent compressible and stretchable in the axial direction. The bare stent is used in the aorta and provided with at least two layers of woven meshes, and is characterized in that the bare stent is provided with a non-sparse-mesh area and a sparse-mesh area; the non-sparse-mesh area is formed by overlapping and interweaving at least two kinds of first wires and second wires with different diameters, the first wires have the diameter of 20-150 microns, and the second wires have the diameter of 150-600 microns; the sparse-mesh area is only composed of the second wires and is arranged at the position, with a branch artery, in the corresponding treatment position after the bare stent is released; and in the natural release state, except the sparse-mesh area, the bare stent has the metal coverage rate of at least 60%. The present invention relates to the bare stent for the treatment of aortic aneurysms and / or aortic dissection lesions, in particular type A aortic dissection, which is axially stretchable and radially compressible in a released state to obtain a delivery configuration of suitable dimensions for performing a procedure using a delivery catheter conventionally delivered through the femoral artery.

The invention relates to pharmaceutical application of hydrogen sulfide synthase (CSE), in particular to application in preparation of drugs for treating aortic aneurysm and aortic dissection. The CSE adeno-associated virus improves the endothelial function and inhibits the onset of aortic aneurysm and aortic dissection. According to the invention, the effect of the hydrogen sulfide synthase CSE on endothelial injury caused by mechanical traction and prevention of aortic aneurysm and aortic dissection is defined. A new means is provided for treating the main aneurysm and the aortic dissection.

The pharmaceutical use of regulating the level of thiol nitrosylation modification of Septin2 belongs to the field of molecular biology diagnosis of aortic aneurysm and aortic dissection. The present invention uses lentivirus infection into macrophages to down-regulate the mercapto nitroso at the Cys111 site of Septin2 protein Kylation modification can effectively inhibit the occurrence of aortic aneurysm and aortic dissection.

The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.

The invention relates to a pharmaceutical application of a lentivirus in regulating the sulfydryl nitrosation modification level of Septin2, belonging to the field of molecular biology diagnosis of aortic aneurysm and aortic dissection. According to the invention, the occurrence of the aortic aneurysm and the aortic dissection can be effectively inhibited by infecting the lentivirus into macrophages to down-regulate the sulfydryl nitrosation modification of the Cys111 site of the Septin2 protein.

The invention relates to application of crocin to preparation of drugs for preventing and / or treating thoracic aorta dissection / aortic aneurysm. The drugs include drugs fed through the gastrointestinal tract, drugs fed through intravenous injection and drugs fed through a subcutaneous embedding mode, and are preferably drugs fed through the subcutaneous embedding mode.

The present invention relates to the use of a compound that can inhibit tyrosine hydroxylase, such as alpha-methyl-p-tyrosine (AMPT), for the prevention or treatment of aortic aneurysm, preferably of the abdominal aortic.

The invention provides pharmaceutical application of a hydrogen sulfide donor, particularly relates to application of hydrogen sulfide and a hydrogen sulfide donor in preparation of medicines for treating aortic aneurysm and aortic dissection, and particularly relates to application of sodium hydrosulfide, DATS, L-cysteine and analogues thereof, GYY4137, ADT-OH and analogues thereof, and Gem-dithiol and analogues thereof in preparation of medicines for treating aortic aneurysm and aortic dissection. According to the invention, through an integral animal model, the hydrogen sulfide and the hydrogen sulfide donor are determined to be capable of reducing the occurrence rate and death rate of aortic aneurysm and aortic dissection, increasing the content of hydrogen sulfide in circulating blood, inhibiting expression of inflammatory factors in the process of aortic aneurysm and aortic dissection, and improving loss of smooth muscle cells in the process of aortic aneurysm and aortic dissection. The hydrogen sulfide donor can be used as a treatment medicine for improving occurrence and development of aortic aneurysm and aortic dissection.

The invention belongs to image analysis, and in particular relates to an aneurysm image analysis system, method and device based on dual-flow boundary perception, aiming to solve the problem that the existing image analysis technology cannot accurately analyze the image of aneurysm based on the developed image. The present invention includes: acquiring a DSA image of a region containing an aortic aneurysm as an image to be detected, based on the image to be detected, generating an aortic aneurysm boundary feature image and an aortic aneurysm image mask through a trained two-stream boundary perception network, based on The aortic aneurysm image mask and the aortic aneurysm boundary feature are combined with the DSA image to obtain morphological information of the aortic aneurysm image. The invention improves the accuracy of aneurysm images and solves the problem of blurred boundaries of aneurysm images in the prior art by inputting the extracted features into a dual-stream boundary perception network, simultaneously extracting boundary features and mask images and merging them. Accurate aneurysm morphology analysis.

A class of oral GSNOR inhibitors and pharmaceutical applications thereof, the invention has good oral bioavailability and longer half-life. In vitro experiments, the compound of the present invention can improve the reduction of migration ability and tube-forming ability of human umbilical vein endothelial cells caused by high glucose, and the increase of permeability; Neogenesis and blood flow recovery suggest that the compound of the present invention can be used for treating diseases related to diabetic vascular complications. The compound of the present invention can improve the smooth muscle cell phenotype conversion caused by angiotensin II, and the compound of the present invention can obviously improve the incidence and mortality of aortic aneurysm / dissection, suggesting that the compound of the present invention can be used for the treatment of diseases related to aortic aneurysm / dissection . The compound of the present invention can effectively inhibit the activity of GSNOR, suggesting that the compound of the present invention can be used for treating diseases related to asthma and cystic fibrosis.

The present invention addresses the problem of providing a therapeutic agent for an abdominal aortic aneurysm, the therapeutic agent making drug therapy possible.The present invention provides a therapeutic agent for aortic aneurysm, the therapeutic agent having as active ingredients: (−)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt thereof, or a solvate of these; and a statin.